RxDoctor Payments Data

Rebecca Noll

Psychiatric/Mental Health · Baltimore, MDNPI 1720752173

Payments from drug & device makers

$4,495in general payments, 2019–2025

Across 195 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$810
  • AbbVie$542
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$488
  • Lundbeck LLC$420
  • Otsuka America Pharmaceutical, Inc.$399
  • Neurocrine Biosciences, Inc.$358
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,43499%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,495 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$7,755
Medicare patients
18
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl11$15,654
TrintellixVortioxetine Hydrobromide22$10,365
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine61$1,821
Hydroxyzine Hcl47$1,404
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine34$1,391
Trazodone Hcl28$990
Mirtazapine67$943
Quetiapine Fumarate46$920
Buspirone Hcl45$673
Clonazepam96$615
Escitalopram Oxalate40$478
Propranolol Hcl19$413
Bupropion XlBupropion Hcl14$407
Aripiprazole37$406
Divalproex Sodium ErDivalproex Sodium11$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$542$15,65411 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$111$10,36522 claims
Almatica Pharma LLCSertraline Hcl$81$21837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →